NRAS (Neuroblastoma RAS viral oncogene homolog)

These findings underscore the genetic heterogeneity of NS and emphasize the importance of early molecular diagnosis to guide clinical management. Multidisciplinary follow-up is essential due to the risks of growth failure, cardiac anomalies, and malignancies.

Given the patient's advanced age and underlying MF, two cycles of a low-intensity chemotherapy regimen primarily based on the "VP regimen (Vincristine + Prednisone) combined with Azacitidine" were administered...Patient tolerability to intensive chemotherapy and novel targeted agents (e.g., Venetoclax) is poor, leading to a dismal prognosis...This case not only serves as a unique model illustrating the complex evolution of a malignant clone but also profoundly reveals the unique therapeutic challenges and extremely poor survival outcome resulting from the convergence of advanced age, MF background, and MPAL transformation. It offers pivotal real-world evidence for the clinical management of this specific patient population and highlights the need to explore novel therapeutic strategies.

Importantly, using mouse models of liver cancer, we show that RBM39 and SF3B1 inhibitors are effective in targeting both preneoplastic lesions and aggressive tumours expressing oncogenic RAS. In summary, our study highlights the spliceosome as a promising target for RAS-driven cancers capable of inhibiting both cancer initiation and progression.

This case underscores the importance of early response evaluation in ICI-treated MSI-H tumors. Rapid disease progression requires prompt differentiation between HPD and pseudoprogression, emphasizing the necessity of timely therapeutic modification.

In HER2+ breast cancer, PIK3CA mutations were significantly associated with reduced response to dual HER2 blockade with pertuzumab+trastuzumab as well as reduced response to nab-paclitaxel. This reduction was not observed in GeparTrio without anti-HER2 therapy.

We report the case of a patient with metastatic foot melanoma enrolled in a clinical trial of the anti-RAS agent RMC-6236 who developed chronic bilateral corneal epithelial defects and thinning, likely secondary to the systemic effects of targeted therapy. This case highlights the ocular surface toxicity associated with systemic anticancer therapies affecting rapidly dividing cells and the overall importance of multidisciplinary medical management of these systemic therapeutics.

The prognostic relevance of "NRAS + SETBP1", "ASXL1 + RUNX1", NPM1 and BCOR was validated in an external cohort from Italy (N = 501). Taken together, these observations highlight i) the possibility of prognostic interaction of mutations in CMML that should be considered in the development of future risk models and ii) the distinct genotypic and prognostic characteristics of NPM1-mutated CMML.

P1, N=300, Recruiting, Kura Oncology, Inc. | N=66 --> 300

NRAS was the most frequent mutation, followed by ARID1A, CDK4, CDKN2A, JAK2 and MYC, without a significant association with survival. These results emphasise the prognostic value of mitotic index and surgical completeness, while confirming the marked molecular heterogeneity of mucosal melanoma and the lack of a single dominant actionable alteration.

cfDNA from fine-needle aspiration rinses provides a highly reliable and efficient substrate for molecular testing in metastatic melanoma, outperforming CB-based analysis in terms of sample adequacy. This approach preserves cellular material for ancillary studies and may reduce false-negative results. Prospective studies using broader next generation sequencing panels are warranted to confirm analytical robustness and clinical utility.

STAT3/STAT5 mutations are early, dominant, and potentially pathogenic events in plasma cell myeloma. Their association with adverse clinical features and inferior survival supports their routine assessment and potential therapeutic targeting.

In conclusion, the DMBA-induced leukemia rat model exhibits a transcriptomic profile that closely mirrors key oncogenic and prognostic features of human leukemia. This model holds significant promise for preclinical studies targeting leukemogenesis and therapeutic intervention strategies.